Dexcom (DXCM) Shares Outstanding (Weighted Average) (2010 - 2026)

Dexcom (DXCM) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $385.1 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) fell 1.53% year-over-year to $385.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $385.1 million (down 1.53% YoY) and the FY2025 annual result came in at $390.2 million, down 0.86% from the prior year.
• Shares Outstanding (Weighted Average) retreated to $385.1 million in Q1 2026 per DXCM's latest filing, from $390.2 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $399.2 million in Q2 2024 and bottomed at $385.1 million in Q1 2026.
• The 5-year median for Shares Outstanding (Weighted Average) is $390.2 million (2024), against an average of $390.1 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 303.84%; it then fell 1.9% in 2025.
• Tracing DXCM's Shares Outstanding (Weighted Average) over 5 years: stood at $389.4 million in 2022, then fell by 0.87% to $386.0 million in 2023, then grew by 1.97% to $393.6 million in 2024, then decreased by 0.86% to $390.2 million in 2025, then decreased by 1.31% to $385.1 million in 2026.
• Per Business Quant, the three latest DXCM Shares Outstanding (Weighted Average) figures stand at $385.1 million (Q1 2026), $390.2 million (Q4 2025), and $391.4 million (Q3 2025).

Peer Comparison